Calumet, Inc. enters the back half of August with an unusually clean setup: a stock up 11% on the week, short sellers cutting exposure at the fastest pace in months, and options traders rotating away from defensive hedges — all at the same time.
The most striking development this week is the coordinated retreat of the bears. Short interest dropped 9.4% in a single session on August 11, leaving it at 3.9% of the free float — down 17% from a month ago and back to the lowest level since early July. The exit coincides with a strong earnings reaction: Calumet reported on August 7 and jumped 8.6% the next day, a move sharp enough to flush out positions on the wrong side of the trade. With the stock now at $46.04 — up 17% over the past month — shorts who built exposure above $40 are nursing losses.
The lending market tells an uncrowded story. Availability is running at roughly 2,338% — meaning there are more than 23 shares available to borrow for every one already lent out, deep in the "very loose" range. Cost to borrow ticked up 19% on the week to 0.56%, its highest of the recent period, but in absolute terms remains negligible for a stock this active. The ORTEX short score has also declined, slipping from around 43 two weeks ago to 41.4 today — reflecting a market where the conditions for a squeeze are simply not present. Availability this loose has been the norm for months; there is no borrow constraint forcing anyone's hand.
Options positioning reinforces the shift in tone. The put/call ratio has dropped to 0.98, roughly 1.3 standard deviations below its 20-day average of 1.04 — the mirror image of the defensive hedging typical of this name over the summer. For most of July, CLMT ran a PCR above 1.05, suggesting traders were anchoring downside protection. That protection is being unwound now, consistent with the stock clearing the earnings overhang cleanly.
The Street is cautiously acknowledging the move without fully embracing it. TD Cowen's Jason Gabelman raised his price target to $40 (from $34) today while keeping a Hold, and Goldman Sachs moved to $40 on July 30, also from a neutral stance. Both upgrades land below the current price of $46 — a meaningful gap that signals the consensus is still anchored to pre-earnings levels and hasn't fully reset. The one outlier is HC Wainwright, which maintained a Buy with a $60 target back in March. With the consensus rating at Hold and a mean target of $42.20, the Street is essentially telling investors the stock has outrun near-term fair value estimates. EPS momentum scores rank in the bottom decile (2nd percentile on 30-day, 1st percentile on 90-day), and the EV/EBITDA multiple has compressed sharply — down more than three turns over the past month — as the price ran ahead of earnings revisions.
On the ownership side, one number stands out: net insider activity over the past 90 days totalled roughly $21.1 million in value on net positive share accumulation. That's a material figure, though the detail behind it is mostly director award grants from early July rather than open-market purchases. Chairman Stephen Mawer did sell 5,512 shares at $39 on July 9 — well below current levels — suggesting at least some insiders trimmed into strength before the latest leg higher. BlackRock added 401,000 shares as of July 31, and State Street added 485,000 over the same period, both passive flows consistent with index rebalancing after a sharp move up.
Peer context adds texture to the week's move. CLNE dropped 8.6% on the week while PARR fell 9.1%, making CLMT's 11% gain look genuinely idiosyncratic rather than a sector tailwind. VLO, PBF, and MPC each added 5-8% on the week, so broader refining did catch a bid — but CLMT outpaced all of them by a wide margin, driven by its own earnings catalyst rather than macro tailwinds.
The next scheduled earnings date is November 6. Between now and then, the key tension is whether the Street's $42 consensus catches up to the stock, or whether the stock drifts back toward the analysts.
See the live data behind this article on ORTEX.
Open CLMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
